Michael Crichton
Partner
Patent Agent
Article
Most jurisdictions provide at least some procedures for challenging the validity of a granted patent. Sometimes the process for challenging validity is conducted before a patent office, and sometimes the process is conducted in court before a judge (either as a counterclaim, or as a standalone impeachment or declaratory judgment action).
In the United States, the Inter Partes Review (IPR) process, which came into effect in 2012 pursuant to the America Invents Act, has garnered a great deal of attention for being seen as favourable to those challenging patent validity. Indeed, over September 2012 - March 2018, patent validity challengers have in 65% of instituted cases[1] succeeded in having all claims invalidated, and in an additional 16% of instituted cases succeeded in having at least some claims invalidated.[2] Thus, patentees succeed in having all claims survive in only 19% of instituted cases.[3] Moreover, the IPR process has proved frustrating for patentees seeking to enforce their patents in parallel district court litigation, as district courts will frequently stay their litigation pending the resolution of IPR proceedings.
Recently, the Supreme Court of the United States (SCOTUS) heard and decided the Oil States case[4] where the constitutionality of the IPR process was challenged and ultimately upheld.
In view of this recent SCOTUS decision, this article discusses post-grant patent validity challenges in Canada and Europe (with a focus on the U.K.).
On April 24, 2018, the SCOTUS issued its decision in the Oil States case addressing whether the IPR process is constitutional.
Specifically at issue in Oil States was whether the IPR process violated Article III of the US Constitution. Article III has been interpreted to require that certain disputes must be decided by courts, and Congress may not delegate authority to resolve such disputes to a non-Article III court. An exception to this requirement is where the dispute involves a "public right".
In Oil States, the SCOTUS held that the IPR process "falls squarely within the public rights doctrine". "[T]he decision to grant a patent is a matter involving public rights - specifically, the grant of a public franchise. Inter partes review is simply a reconsideration of that grant, and Congress has permissibly reserved the PTO's authority to conduct that reconsideration. Thus, the PTO can do so without violating Article III. "
Accordingly, those wishing to challenge the validity of US patents will continue to be able to use the IPR process for doing so. In addition to the IPR process, patent validity challengers in the United States may avail themselves of the Post-Grant Review (PGR) process,[5] the Covered Business Method (CBM) process, and more traditional declaratory judgment actions (where jurisdiction can be established).
In Canada, there is no equivalent to the Inter Partes Review, Post-Grant Review or Covered Business Method processes.
Canada has two main processes for post-grant challenging of patent validity:
Re-examinations in Canada are rare. There are at least several reasons for this:
Accordingly, outside of exceptional circumstances, any person wishing to challenge a granted patent's validity in Canada will likely be well advised to proceed by way of impeachment action.
In basic terms, there are two systems pursuant to which a patent may be granted covering the UK: the national system and the European system. There is some overlap and there are some differences in how patents granted pursuant to these two systems may be challenged post-grant.
The European patent system (including the European Patent Office (EPO)) was established by the European Patent Convention. It provides for the centralised application, prosecution and grant of patents, as a bundle of national designations, in and by the EPO. The UK designation of a granted European patent has effect in the UK.
Within nine months of grant of a European patent, any person (natural or legal) may file a written opposition to the grant at the EPO, on one of the prescribed grounds (lack of patentability, insufficiency, added matter; EPC Arts. 99-100). The opposition procedure is inter partes. It is largely a written proceeding but with an opportunity for a short oral hearing, and is determined by the EPO's Opposition Division, with appeal lying to an EPO Board of Appeal.
Where an opposition succeeds, or leads to the amendment of the patent, the patent is revoked or amended in respect of all designations for which it was granted. The EPO's decision can therefore have the effect of over-riding any amendments made to the national designation(s) pursuant to national law and procedure.
Approximately 4% of granted European patents are opposed, and in 2016, 72% of the patents were upheld either as granted or in amended form.[8]
Alternatively or in addition, any person may commence proceedings in the UK court or UK Intellectual Property Office ('UK IPO') claiming for revocation of the UK designation of a European patent, as discussed below under the heading "Challenge to UK patents".
The possibility of concurrent proceedings in the EPO and the UK court (or UK IPO), both contesting the validity of the UK designation of a European patent, is inherent in the system established by the EPC. If there are no other factors, the 'default' option is to stay the UK proceedings. However, in practice commercial factors will be weighed up by the court when deciding where the balance lies in any issue of stay. Infringement issues are within the jurisdiction of the UK court but not that of the EPO, EPO opposition proceedings can take years to conclude, and since the need for commercial certainty may weigh against the grant of a stay, a court ordered stay is unusual.
Any person may claim for revocation of a granted UK national patent or the UK designation of a granted European patent before the court or before the Comptroller-General of Patents Designs and Trade marks (the "Comptroller " i.e. the UK Intellectual Property Office). The 'court' is: in England and Wales, the High Court (Patents Court or IPEC); in Scotland, the Court of Session; in Northern Ireland, the High Court. Such challenges are inter partes and proceed according to the rules of the relevant forum.
The grounds upon which revocation may be sought are set out in s.72 of the UK Patents Act 1977. These are that the invention is not patentable (lacks novelty, inventive step or industrial application or is otherwise excluded from protection), that the specification is insufficient or adds matter, or that the protection conferred by the patent has been extended by an amendment which should not have been allowed. Additionally, a person claiming entitlement may seek revocation on the basis that it was granted to a person not entitled.
In the course of such proceedings, the court may, upon the application of the patentee in accordance with the relevant rules, consider and permit amendment to the patent.
Additionally, the Patents Act, s.74A, provides that the proprietor of a patent or any other person may request the Comptroller to issue an opinion on a prescribed matter in relation to the patent. The prescribed matters are defined in the Patents Rules 2007, section 93, and include questions of patentability, sufficiency, added matter and extension of scope. They also include questions of infringement (or non-infringement).
Such opinions are not binding for any purposes. However, where the Comptroller issues an opinion under s.74A that the patent lacks novelty or lacks inventive step, the Comptroller may revoke the patent, but not before the patentee has had the opportunity to seek (and obtain) a review of the opinion. The patent proprietor must also be given an opportunity to make observations and amend the patent.
The opinion procedure offers a relatively low cost means of (potentially) putting in issue the validity of a patent. A copy of all documents received by the UK IPO will be sent to other interested parties, such as the patent owner and any licensee. In some circumstances, the UK IPO may refuse to issue an opinion.
For UK national patents there is no time-limited post-grant opposition procedure equivalent to that available in the EPO in respect of European patents.
Footnotes
[1] Over September 2012 - March 2018, the rate of institution of IPRs has slowly dropped, from 87% in 2013 to 61% in 2018 (to date). See https://www.uspto.gov/sites/default/files/documents/trial_statistics_20180331.pdf. Note that the data presented herein encompasses IPRs, as well as PGRs and CBMs. However, the vast majority of proceedings (92%) relate to IPRs.
[2] https://www.uspto.gov/sites/default/files/documents/trial_statistics_20180331.pdf.
[3] https://www.uspto.gov/sites/default/files/documents/trial_statistics_20180331.pdf.
[4] Oil States Energy Services, LLC v. Greene's Energy Group, LLC, 584 U.S. ___ (2018).
[5] PGRs are available in the nine months after a patent is granted. Numerous grounds related to patent validity may be asserted. This is in contrast to the IPR process where it may be commenced after a PGR or nine months post-patent grant. Only anticipation and obviousness based on patents or printed publications may be asserted in an IPR.
[6] Camso Inc. v. Soucy International Inc., 2016 FC 1116; and, Prenbec Equipment Inc. v. Timberblade Inc., 2010 FC 23.
[7] The methodology for this statistic assumes that a re-examination resulting in all claims maintained, plus half of all re-examinations involving amendments and/or partial cancellations, are a "win " for the patentee.
[8] EPO Facts and Figures 2017
NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.